Souza M E, Polizello A C, Uyemura S A, Castro-Silva O, Curti C
Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Brasil.
Biochem Pharmacol. 1994 Aug 3;48(3):535-41. doi: 10.1016/0006-2952(94)90283-6.
The in vitro and in vivo effects of fluoxetine (and its active metabolite norfluoxetine) on mitochondrial respiration and F0F1-ATPase were studied, respectively, in mitochondria and submitochondrial particles isolated from rat liver. Fluoxetine in vitro inhibited state 3 mitochondrial respiration for alpha-ketoglutarate and succinate oxidations (50% of effect at 0.25 and 0.35 mM drug concentrations, respectively); stimulated state 4 for succinate; and induced a decrease in the respiratory control ratio (RCR) for both oxidizable substrates. The F0F1-ATPase activity was determined at various pH levels in the absence and presence of Triton X-100. The solubilized form was not affected markedly, but an inhibition, apparently non-competitive, was observed for the membrane-bound enzyme, with 50% of the effect at a 0.06 mM drug concentration in pH 7.4. These results suggest that fluoxetine in vitro acts on F0F1-ATPase through direct interaction with the membrane F0 component (similar to oligomycin), or first with mitochondrial membrane and then affecting F0. A very similar behavior concerning the respiratory parameters and F0F1-ATPase properties was observed with norfluoxetine. The in vivo studies with fluoxetine showed stimulation of mitochondrial respiration in state 4 for alpha-ketoglutarate or succinate oxidations in acute or prolonged treatments (1 hr after a single i.p. dose of 20 mg of drug/kg of body weight, and 22 hr after 12 days of treatment with a daily dose of 10 mg/kg of body weight, respectively), indicating uncoupling of oxidative phosphorylation. Pronounced changes were not observed in the K0.5 values of F0F1-ATPase catalytic sites, but the Vmax decreased during the prolonged treatment. The results show that fluoxetine (as well as norfluoxetine) has multiple effects on the energy metabolism of rat liver mitochondria, being potentially toxic in high doses. The drug effects seem to be a consequence of the drug and/or metabolite solubilization in the inner membrane of the mitochondria.
分别在从大鼠肝脏分离出的线粒体和亚线粒体颗粒中,研究了氟西汀(及其活性代谢产物去甲氟西汀)对线粒体呼吸和F0F1 - ATP酶的体外和体内作用。体外实验中,氟西汀抑制了α - 酮戊二酸和琥珀酸氧化的线粒体呼吸状态3(在药物浓度分别为0.25和0.35 mM时,抑制效果达50%);刺激了琥珀酸的呼吸状态4;并导致两种可氧化底物的呼吸控制率(RCR)下降。在有无Triton X - 100的情况下,在不同pH水平下测定F0F1 - ATP酶活性。溶解形式未受到明显影响,但观察到膜结合酶受到明显的非竞争性抑制,在pH 7.4时,药物浓度为0.06 mM时抑制效果达50%。这些结果表明,体外实验中氟西汀通过与膜F0成分直接相互作用(类似于寡霉素)作用于F0F1 - ATP酶,或者先与线粒体膜相互作用,然后影响F0。去甲氟西汀在呼吸参数和F0F1 - ATP酶特性方面表现出非常相似的行为。氟西汀的体内研究表明,在急性或长期治疗中(单次腹腔注射20 mg药物/kg体重1小时后,以及每日剂量10 mg/kg体重治疗12天后22小时),α - 酮戊二酸或琥珀酸氧化的线粒体呼吸状态4受到刺激,表明氧化磷酸化解偶联。F0F1 - ATP酶催化位点的K0.5值未观察到明显变化,但在长期治疗期间Vmax下降。结果表明,氟西汀(以及去甲氟西汀)对大鼠肝脏线粒体的能量代谢有多种影响,高剂量时可能具有毒性。药物作用似乎是药物和/或代谢产物在线粒体内膜中溶解的结果。